Release date: 2024-08-16 16:50:15 Article From: Lucius Laos Recommended: 143
Selpercatinib helps control the proliferation and metastasis of cancer cells by blocking the RET signaling pathway. The drug, which is indicated for patients over 12 years of age, was first marketed in the United States in 2020 and has now been approved for domestic marketing.
When using Selpercatinib for treatment, please refer to the following medication guidelines.
The dose is 9 mg once daily for the first 14 days of each 21-day cycle.
The dose is 4.5 mg once daily for the first 14 days of each 21-day cycle.
For cases that require dose reduction, patients should continue to take 4.5 mg once daily for the entire duration of each 21-day cycle.
Selpercatinib has shown significant results in the treatment of the following aspects.
Results in patients with RET fusion-positive non-small cell lung cancer
Fourteen patients responded to intracranial lesions, demonstrating the effectiveness of treatment for brain metastases.
Intracranial remission lasted more than 12 months in 39% of patients, suggesting that in some patients, treatment can control brain metastases in the short term and achieve long-term intracranial stability.
There are some side effects that may result from the use of Selpercatinib, and common reactions are listed below.
Similar to the adverse effects of cholangiocarcinoma, hyperphosphatemia is a condition in which phosphate levels in the blood rise, which can cause muscle cramps, bone pain, and other problems. Patients need to have their blood phosphate levels checked regularly and their diet and medications adjusted under the guidance of their doctor to manage their symptoms.
Patients may have discoloration, brittleness, or delamination of their nails, affecting the appearance and function of the nails. This adverse effect may be uncomfortable for the patient, and it is important to protect the nails as much as possible in daily life, keep the hands clean, and avoid exposure to harsh chemicals.
[Warm tips] Take the medicine strictly according to the dosage requirements on the doctor's or drug instructions. Do not increase or decrease the dosage without authorization, as it may affect the effectiveness of the medication or increase the risk of side effects.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: